Sign in
FRNM Stock Price, Chart, Stats & News
Freenome, Inc.
Save
Freenome, Inc. (FRNM) does not currently pay a dividend.
133.04M
Market cap
–
Current P/E
–
Forward P/E
FRNM chart
1M
3M
1Y
5Y
Loading chart...
About
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome's first commercial-stage test, SimpleScreen CRC for colorectal cancer, is under review by the U.
Similar securities
Based on sector and market capitalization
Report issue